Maplelane Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Maplelane Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	–	–	160
2018 Q3	$0	Buy	+1	New	+$381	﹤0.01%	159

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Maplelane Capital's REGN Position: Q4 2018 in Review

Maplelane Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2018, closing a stake of 1 share.

Maplelane Capital first reported a position in REGN in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 670 funds tracked by Wall St. Rank hold REGN as of Q4 2018.

Maplelane Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Maplelane Capital sold 1 Regeneron Pharmaceuticals share in Q4 2018.
Maplelane Capital first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Maplelane Capital's Regeneron Pharmaceuticals position peaked at $0 in Q3 2018.
670 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2018.

Based on Maplelane Capital's 13F filing for Q4 2018, filed 14 Feb 2019.